drugset / Trial / NCT06150703
Luteal Phase Support With GnRH Agonist After GnRH Agonist Triggering in IVF/ICSI Cycles
RandomizedParallel-groupOpen-labelTreatment
Summary
The development of stimulation protocols for in vitro fertilisation (IVF) has led to a paradox. It has now been established that obtaining a large number of oocytes is a key to success, but that it is also a risk factor for embryo transfer failure after puncture (disruption of endometrial receptivity due to luteal insufficiency) and a risk factor for complications such as ovarian hyperstimulation syndrome (OHSS).
Timeline
- Start
- 2024-06-27
- Primary completion
- 2027-09
- Completion
- 2027-09-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nafarelin | Other / unclassified | 200 ug | Intranasal |
| Comparator | Progesterone | Other / unclassified | 200 mg | Intravenous |
| Subject | Triptorelin | Other / unclassified | 0.2 mg | Subcutaneous |
| Comparator | hCG | Unknown | 250 ug | Subcutaneous |
Indications
No indication recorded.